PointState Capital LP grew its holdings in shares of Humana Inc (NYSE:HUM) by 13.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 14,200 shares of the insurance provider’s stock after purchasing an additional 1,700 shares during the period. PointState Capital LP’s holdings in Humana were worth $4,226,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Victory Capital Management Inc. increased its position in shares of Humana by 455.5% during the first quarter. Victory Capital Management Inc. now owns 13,737 shares of the insurance provider’s stock valued at $3,693,000 after acquiring an additional 11,264 shares in the last quarter. Engineers Gate Manager LP increased its position in shares of Humana by 26.3% during the first quarter. Engineers Gate Manager LP now owns 6,708 shares of the insurance provider’s stock valued at $1,803,000 after acquiring an additional 1,395 shares in the last quarter. Synovus Financial Corp bought a new stake in shares of Humana during the first quarter valued at approximately $100,000. Thrivent Financial for Lutherans increased its position in shares of Humana by 16.3% during the first quarter. Thrivent Financial for Lutherans now owns 6,782 shares of the insurance provider’s stock valued at $1,823,000 after acquiring an additional 953 shares in the last quarter. Finally, Neuberger Berman Group LLC increased its position in shares of Humana by 61.7% during the first quarter. Neuberger Berman Group LLC now owns 8,896 shares of the insurance provider’s stock valued at $2,392,000 after acquiring an additional 3,395 shares in the last quarter. Hedge funds and other institutional investors own 93.00% of the company’s stock.

In other news, insider Timothy Alan Wheatley sold 11,468 shares of the business’s stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $299.40, for a total transaction of $3,433,519.20. Following the completion of the sale, the insider now owns 3,889 shares of the company’s stock, valued at approximately $1,164,366.60. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Elizabeth D. Bierbower sold 3,092 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the sale, the insider now directly owns 14,289 shares of the company’s stock, valued at approximately $4,715,370. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,752 shares of company stock valued at $16,581,234. Insiders own 0.60% of the company’s stock.

NYSE:HUM opened at $337.24 on Friday. Humana Inc has a 12 month low of $231.90 and a 12 month high of $339.88. The company has a quick ratio of 1.43, a current ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $45.68 billion, a price-to-earnings ratio of 28.80, a P/E/G ratio of 1.65 and a beta of 0.96.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The firm had revenue of $14.26 billion during the quarter, compared to the consensus estimate of $14.16 billion. During the same quarter in the previous year, the firm posted $3.49 EPS. sell-side analysts forecast that Humana Inc will post 14.18 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Stockholders of record on Friday, September 28th will be given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, September 27th. Humana’s payout ratio is 17.08%.

HUM has been the subject of several analyst reports. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Friday, May 18th. Citigroup reaffirmed a “buy” rating and issued a $340.00 target price (up previously from $280.00) on shares of Humana in a research report on Friday, June 1st. ValuEngine downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Saturday, June 2nd. BMO Capital Markets lifted their target price on shares of Humana from $328.00 to $355.00 and gave the stock an “outperform” rating in a research report on Monday, June 25th. Finally, Piper Jaffray Companies lifted their target price on shares of Humana from $326.00 to $350.00 and gave the stock an “overweight” rating in a research report on Friday, July 6th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $331.11.

About Humana

Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.

Further Reading: Do Tariffs Work?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.